You're reading: Wall Street Journal: Coronavirus vaccine candidate from Pfizer, BioNTech produces positive results in early study

Wall Street Journal: Coronavirus vaccine candidate from Pfizer, BioNTech produces positive results in early study

By Wall Street Journal.

Published July 2, 2020 at 5:06 am

A scientist is pictured working during a visit by Britain's Prince William, Duke of Cambridge (unseen), to Oxford Vaccine Group's laboratory facility at the Churchill Hospital in Oxford, west of London on June 24, 2020, on his visit to learn more about the group's work to establish a viable vaccine against coronavirus COVID-19.

Photo by AFP

Researchers said an experimental coronavirus vaccine from Pfizer Inc. and partner BioNTech SE showed promising signs of working in an early-stage study. Healthy adult volunteers given the vaccine candidate had higher levels of antibodies four weeks after being vaccinated and seven days after getting a second dose, compared with the antibody levels in recovered Covid-19 patients who didn’t get the shots, the researchers reported Wednesday.